Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
Hikmat Abdel-RazeqDepartment of Internal Medicine, Section of Hematology and Medical Oncology, King Hussein Cancer Center and School of Medicine, University of Jordan, Amman, JordanAbstract: Breast cancer remains the most common cancer among women worldwide. Many patients, especially in our region,...
Main Author: | Abdel-Razeq H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-05-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/gonadotropin-releasing-hormone-agonists-during-chemotherapy-for-ovaria-peer-reviewed-article-CMAR |
Similar Items
-
Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells
by: Kuan-Hao Tsui, et al.
Published: (2014-03-01) -
Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin‐releasing hormone agonist for women undergoing fertility preservation
by: Yeon Hee Hong, et al.
Published: (2022-01-01) -
Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles
by: Muammer Doğan, et al.
Published: (2012-06-01) -
Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome. A randomized trial
by: Amr Hassaan Farag, et al.
Published: (2015-12-01) -
Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
by: Behnaz Khani Rabati, et al.
Published: (2012-01-01)